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Abstract
Background Children are still prescribed age contraindicated drugs, but information about the number and type of these drugs 
dispensed for children in the Netherlands is limited. Objective To determine the incidence and prevalence of contraindicated 
drugs that were dispensed for the use by children. Setting The study was conducted in the Netherlands with routinely collected 
data from 95% of all community pharmacies. Method We performed a one-year nationwide observational study where all 
patients aged 17 years or younger who have received at least one prescription in 2016 were included. Contraindicated drugs 
were selected, according to the 5th level of ATC code, using different information sources. Main outcome measure The 
proportion of (newly) contraindicated drugs that were dispensed to children. Results In total, 3.9% of all children received 
at least one drug that was contraindicated for their age. The highest percentage of contraindicated drugs that was dispensed, 
was observed in patients aged 1–2 years and 13–17 years (7.0 and 5.7%, respectively) and the percentage of contraindicated 
drugs that were dispensed was higher in female than in male patients (4.3 and 3.6%, respectively; p value < 0.001). Conclu-
sion The results of this study show that a substantial percentage of children received a drug that was conta-indicated for their 
age, and  it happes more in female than in male patients. Furthermore, the information about this type of contraindications 
is limited and inconsistent.
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Impact of findings
• Information about contraindications or warnings should 
be improved to support prescribers and other healthcare 
professionals when prescribing contraindicated drugs 
which are deemed necessary.
• It is not clear why contraindicated drugs are more 
often prescribed for female than male children. Further 
research in this field should be carried out to address 
these gender differences and to improve our knowledge 
about the safety of drugs  in thse patient groups.
Introduction
Many drugs are prescribed off-label because they are not 
approved for use in children [1, 2]. GPs and other prescrib-
ers make decisions based on the available evidence, which 
can be very limited. Drugs used for treating children are 
often insufficiently documented with regard to dosing, effi-
cacy, and safety in this patient group. When off-label use is 
associated with a safety hazard or a risk of serious adverse 
drug reactions, it is described as a contraindication, which 
means that there is sufficient evidence that the drug is or 
might be harmful and use of these drugs is not advised. [3]. 
In some circumstances there is insufficient information avail-
able about the use of drugs in children. In this case, it is 
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acceptable to prescribe these drugs if the benefits outweigh 
the risks (warning). Contraindications are always described 
in the labels of the products concerned and should be strictly 
followed to ensure safe use of these drugs in a specific popu-
lation [4].
One of the recent examples is the label revision for prod-
ucts containing codeine and tramadol which states that these 
drugs are contraindicated for the treatment of pain in chil-
dren younger than age 12. Adverse event reports showed that 
the use of codeine was associated with respiratory depres-
sion and death, with the majority of cases involving chil-
dren under the age of 12 [5]. This contraindication shows 
that it is important for healthcare professionals to know that 
prescribing these drugs to children from this particular age 
group should be avoided and alternatives should be used 
instead. However, in some cases, contraindicated drugs are 
still prescribed when there is a great burden of disease and 
no alternatives are available [6]. In other cases it is also pos-
sible that prescribers were not aware of the contraindications 
in the drug labelling [6].
Numerous studies have described the contraindication 
of medication use in relation to specific diseases or patient 
characteristics, but the focus on age and gender in children 
in these studies is very limited [7–9]. Moreover, these stud-
ies are often based on prescription data and it is not always 
clear if these drugs were actually dispensed.
Aim of the study
To determine the incidence and prevalence of contraindi-
cated drugs dispensed to children, with routinely collected 
data from community pharmacies in the Netherlands.
Ethics approval
Informed consent was not required, since this was an obser-
vational, non-interventional cohort study.
Method
Setting
Data were obtained from the Dutch Foundation for Phar-
maceutical Statistics (Stichting Farmaceutische Kengetal-
len). This database contains dispensing data from 95% of 
all community pharmacies in the Netherlands since 1990 
[10]. In the Netherlands, the community pharmacies dis-
pense the vast majority of all out-patient prescriptions. For 
each dispensing, the following information is available: a 
unique anonymised patient code, gender and year of birth, 
product name, active substance according to the Anatomic 
Therapeutical Chemical code (ATC code) [11], dispensing 
date, total number of drug units per prescription, prescribed 
daily number of units, dosage, regimen, type of prescriber 
(GP, specialist or other healthcare professional) and the first 
two digits of the postal code indicating the region.
Cohort definition
All patients aged 17 years or younger who have received 
at least one prescription during the study period between 1 
January 2016 and 31 December 2016 were included. Patients 
with an unknown gender were excluded.
Measures
Drugs that are contraindicated in children were selected 
according to the  5th level ATC code of the World Health 
Organisation [11]. The prescription codes (PRK code) were 
used if products had to be selected on substance level. The 
primary reference source that was used to determine the 
contraindication status in children was the Farmacothera-
peutisch Kompas 2016 (a national formulary provided by the 
National Health Care Institute) because it contains informa-
tion of all drugs and most details about the topic of interest 
[12]. The descriptions in the Farmacotherapeutisch Kom-
pas are written based on the information in the summary 
of product characteristcs (SmPC), which is considered as a 
legal document that was approved by the Medicines Evalu-
ation Board or the European Medicines Agency. The alter-
native source of information was the SmPC of the products 
concerned, which was used in case of conflicting informa-
tion from different sources. Furthermore, the Kinderfor-
mularium (national formulary for children) was used when 
the information about the contraindication was not clearly 
described [13]. The following drugs that are contraindicated 
in children below 6 months of age were excluded from the 
analysis as only the year of birth was available: atazanavir, 
cotrimoxazol, fluticasone, hydrocortison (systemic), meth-
ylprednisolone, nandrolone, sodium polystyrene sulfonate, 
pethidine, prilocaine, somatropin, sulfadiazine, tocofersolan 
and vitamine B complex (parenteral).
Analysis
For all patients, we determined the number of drugs dis-
pensed between 1 January 2016 and 31 December 2016. In 
our study, a person was identified as user of a contraindi-
cated drug when having at least one contraindicated drug 
dispensed during the study period. In the analyses, we have 
calculated the cumulative 1-year incidence as the propor-
tion of the total cohort to which a contraindicated drug was 
dispensed in the year 2016 for the first time since birth. 
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In addition, the cumulative 1-year prevalence was deter-
mined by the proportion of children with a contraindicated 
drug dispensed in the study period, including those who 
had started before 1 January 2016. This was also stratified 
according to age, which was classified into five groups: 
< 1 year, 1–2 years, 3–6 years, 7–12 years and 13–17 years. 
In addition, we investigated the gender differences and we 
calculated the number of contraindicated drugs that were 
dispensed per region and per type of prescriber. The analyses 
included almost the entire Dutch population and therefore 
the calculation of confidence intervals for the incidence and 
prevalence were not deemed necessary. We also investigated 
the information available in the Farmacotherapeutisch Kom-
pas, SmPC, Kinderformularium about the reasons for a drug 
to be contraindicated, which are classified into the active 
ingredient, high/unknown dosage, formulation, lack of infor-
mation about efficacy or safety and the presence of excipi-
ents. Finally, we have calculated the number of patients, the 
number of drugs that were dispensed and mean age for the 
most commonly dispensed contraindicated drugs.
Results
Patients with an unknown gender (n = 122,144) were 
excluded from the analysis. The remaining 1,527,021 
patients received at least one drug in 2016 where 3.9% of 
these patients received a drug that was contraindicated for 
age (Table 1). The cumulative prevalence was significantly 
higher in females compared to males (4.3% and 3.6%, 
respectively; p value < 0.001) and highest in patients aged 
1–2 years (7.0%). The majority of patients received only one 
type of drug that was contraindicated for age in the study 
period (1 drug: 58,597 (6.0%); 2 or more: 1,496 (0.3%)).
The number of new users of a contraindicated drug in 
2016 was 43,206 (2.8%), which was significantly higher 
in females (3.1%) than in males (2.6%) (p value < 0.001). 
The cumulative incidence was highest in the age categories 
1–2 years (5.5%) and 13–17 years (4.2%), followed by the 
age categories 0–1 (2.3%), 7–12 years (1.8%) and 3–6 years 
(0.6%). The postal code information available for each 
patient indicated that the number of patients who received 
a contraindicated drug in the Netherlands is fairly equally 
distributed (North 4.0%; East 3.9%; West 3.9% and South 
4.0%). The majority of patients received the contraindicated 
drugs from their GP (n = 1,256,213), followed by medical 
specialists (n = 314,836) and other healthcare professionals 
(n = 206,563) but the contraindicated drugs were neverthe-
less relatively more often prescribed by medical specialists 
than by GPs (GP 3.4%, specialist 4.2% and other 3.6%). The 
most common drugs that were relatively more often pre-
scribed by specialist than GPs or other healthcare profes-
sionals are hydrocortisone/neomycin/polymyxin B (special-
ist: 1.26%, GP: 0.48% and other healthcare professionals: 
0.37%), atropine (specialist: 0.26%; GP:0.003% and other 
healthcare professionals: 0.03%) and dimetindene (special-
ist: 0.23%; GP:0.06% and other: 0.08%).
Overall, the number of patients who received a contraindi-
cated drug was significantly higher in females than in males 
(4.3 and 3.6%, respectively; p value < 0.001) (Table 2). 
Higher percentages were observed for female patients in 
the higher age groups (7–12 years: 3.0%, 13–17 years: 
6.5%) compared with male patients (7–12 years: 2.5%, 
13–17 years: 4.6%). For male patients, higher numbers 
Table 1  Children aged 0–17 years who were prescribed contraindicated drugs in 2016
a The number of different drugs was determined based on the ATC7-codes
Number of children who 
received drugs
Number of children who received a 
contraindicated drug (%)
Number of dispensed 
drugs
Number of dispensed 
contraindicated drugs 
(%)
Overall 1,527,021 60,093 (3.9) 4,454,048 105,106 (2.3)
Gender
Male 769,903 27,604 (3.6) 2,370,735 48,481 (2.0)
Female 757,118 32,489 (4.3) 2,083,313 56,625 (2.7)
Age
< 1 year 59,163 2,289 (3.9) 129,022 2,901 (2.2)
1–2 years 214,506 15,114 (7.0) 277,841 21,295 (7.6)
3–6 years 336,202 3,093 (0.9) 762,978 5,198 (0.7)
7–12 years 429,485 11,731 (2.7) 1,253,424 20,456 (1.6)
13–17 years 487,665 27,866 (5.7) 2,030,783 55,256 (2.7)
Number of different drugsa
1 drug 972,451 58,597 (6.0) – –
2 or more 554,570 1,496 (0.3) – –
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were observed in the lower age groups (< 1 year: 4.1%, 
1–2 years: 7.7%) than in female patients (< 1 year: 3.6%, 
1–2 years: 6.2%). Cholecalciferol (females: 2.5% and males 
1.5%) and metoclopramide (females: 0.5% and males: 
0.3%) were relatively more often prescribed to females than 
males. Hydrocortisone/neomycine/polymyxine B (males: 
0.8% and females: 0.5%) and dimetidene (males: 0.13% and 
females: 0.08%) were relatively more often prescribed to 
male patients.
One of the most common contraindications is due to the 
active pharmaceutical ingredient, which is seen in 49 types 
of drugs and in 25,875 patients (Table 3). Drugs that are 
contraindicated due to the formulation (e.g. difficulty swal-
lowing) was only observed in one type of drug and in 180 
patients.
Figure 1 shows that cholecalciferol is one of the most 
frequently dispensed drugs that is contraindicated for age. 
The combination of hydrocortisone/neomycin/polymyxin 
b, doxycycline, dimetindene, atropine and clobetasol were 
also in the top ten of the most commonly dispensed con-
traindicated drugs, but these drugs were relatively less 
dispensed to children with an age that is within the con-
traindication age limit. The other 15 most commonly dis-
pensed drugs were: fludrocortisone/neomycine/polymyxin 
B/lidocaine, lidocaine, promethazine, etoricoxib, meloxi-
cam, levodopa/benserazide, temazepam, zolpidem, insulin, 
zopiclone, rhubarb extract/salicylic acid, loperamide, sco-
polamine, norfloxacin (systemic) and sodium phosphate 
(rectal) (results not shown due to low numbers).
Table  4 shows more detailed information from the 
most commonly dispensed drugs with a contraindication 
for age. For a number of drugs the actual number of con-
traindicated drugs dispensed is lower than the group that 
was selected based on the ATC codes. Cholecalciferol was 
dispensed to 30,301 children, where 15,988 children (53%) 
received the oral suspension which is contraindicated 
because of its high dose of vitamin D. Metoclopramide 
was dispensed to 6253 patients where 110 patients (1.8%) 
were below the age of 1. The metoclopramide supposito-
ries which are contraindicated in children and adolescents 
less than 18 years, were dispensed to 3559 children (57% 
of the total number). Doxycycline was dispensed to 2,670 
children with an age lower than 12 years, of whom 305 
were less than 8 years (11.4%). Furthermore, 268 patients 
received the drug with the ATC code N04BA02 which 
not only includes levodopa/benserazide, but also levodopa/
carbidopa. The contraindicated drug levodopa/benserazide 
was dispensed to 93 patients (35%). Other commonly dis-
pensed drugs that are contraindicated in children below 
the age of 2 years are dimetindene, levomenthol, promet-
hazine, loperamide, fludrocortisone/neomycin/polymyxin 
B and lidocaine. Temazepam and zoplicon are contraindi-
cated for age because the effectiveness and safety of use 
in children have not been studied yet.
Table 2  Children who were 
prescribed contraindicated 
drugs per age group, stratified 
by gender
Age Male Female
Total Contraindicated (%) Total Contraindicated (%)
All ages 769,903 27,604 (3.6) 757,118 32,489 (4.3)
<1 year 33,201 1357 (4.1) 25,962 932 (3.6)
1–2 years 116,332 9007 (7.7) 98,174 6107 (6.2)
3–6 years 177,066 1668 (0.9) 159,136 1425 (0.9)
7–12 years 232,991 5812 (2.5) 196,494 5919 (3.0)
13–17 years 210,313 9760 (4.6) 277,352 18,106 (6.5)
Table 3  Different type of reasons for age-related contraindications
*Only contraindicated drugs that were dispensed to children by community pharmacies in the Netherlands in 2016 were included
n number
Reason for contraindication Number of different types of drugs with a con-
traindication for age (n = 63)* n (%)
Number of patients receiving a con-
traindicated drug (n = 60,093) n (%)
Active ingredient 49 (77.8) 25,875 (43.1)
High dosage or unknown dosage 7 (11.1) 32,323 (53.8)
Formulation 1 (1.6) 180 (0.3)
Lack of information about efficacy or safety 3 (4.8) 1675 (2.8)
Presence of excipients 3 (4.8) 40 (0.1)
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Discussion
It is not always clear why a drug is contraindicated and how 
many of these drugs are prescribed to children despite their 
contraindication for age. In this nationwide study, we have 
calculated the incidence and prevalence of drugs with a con-
traindication for the age groups to which they were never-
theless dispensed. In our study we observed that 3.9% of all 
children received at least one drug that was contraindicated 
for age, which are mainly newly prescribed drugs (2.8%). 
These results are almost similar to the results observed in 
the study by Bensouda-Grimaldi et al. (3.2%) [6]. Our results 
also showed that male patients received more overall pre-
scriptions than female patients, but contraindicated drugs 
were relatively more often dispensed to female patients. The 
difference in drug use may partly be explained by gender dif-
ferences such as the variation in disease prevalence or sever-
ity, but the differences in health care may also explain this 
observation [14–17]. Further research is needed to address 
the gender differences in prescribing drugs to children.
Alternatives are available for many contraindicated 
drugs, but in some circumstances the contraindicated drug 
is needed. Prescribing an on-label drug does not always 
have to be accurate, whereas prescribing a contraindicated 
drug does not have to be considered bad practice either. 
One of the examples is the oral suspension cholecalcif-
erol which is contraindicated because of the high dose of 
vitamin D. These drugs are necessary for children with 
an impaired vitamin D absorption such as cystic fibrosis 
or serious vitamin D deficiency in rachitis. However, it 
is not clear if they were all prescribed for these type of 
indications, as we observed a large number of patients 
who received the high dose of Vitamin D in our study. The 
increase of vitamin D use since the global recognition of 
vitamin D deficiency in the general population has also 
led to an increase in vitamin D intoxications, which were 
partly due to inappropriate prescribing [18]. This may 
also be explained by the differences between information 
sources that was observed as the oral suspension with a 
high dose of vitamin D was only mentioned in the Farma-
cotherapeutisch Kompas, but not mentioned or described 
in the Kinderformulary. Specialists, GPs or other health-
care professionals may use different information sources 
as we also observed that not only specialist were more 
likely to prescribe contraindicated drugs, but also the type 
of drugs between specialists and GPs together with other 
healthcare professionals were slightly different.
Metoclopramide is still prescribed for chronic use for 
the indication symptomatic gastroesophageal reflux as 
the substantial need is not met by other medications [19]. 
However, the contraindication of metoclopramide sup-
positories in higher age groups is not very clear as it is 
described as a contraindication, but was also described as 
a warning according to the same information source [20]. 
Another commonly prescribed drug that is contraindi-
cated in children is doxycycline, which should be avoided 
because of its known adverse effect; tooth staining [21]. 
It is possible that doxycycline is still prescribed despite 
the label warning as it is considered as one of the most 
effective treatments for tick borne diseases or because 
recent studies showed no visible dental staining in chil-
dren [22–24].
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Fig. 1  The 10 most commonly prescribed drugs with a contraindication for age: users within the contraindication age limit versus users outside 
the contraindication age limit in absolute numbers
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Strengths and limitations
One of the strengths of our study is that we used a popula-
tion-based dispensing database which registers drugs that 
were dispensed in more than 95% of all community pharma-
cies in the Netherlands. Pharmacists play an essential role 
in drug safety and it is likely that the number of contraindi-
cated drugs is higher in prescription data than in our study 
as we have used dispensing data. Detailed information was 
available on all drugs that were dispensed to children. The 
relatively long history available also enabled us to study any 
Table 4  Additional information on the most commonly prescribed contraindicated drugs
a The number of patients are counted based on the ATC codes. The numbers of patients who have received the medication within the age limit for 
contraindication are shown. Patients outside the age limit were excluded
b The number of drugs dispensed are counted based on the ATC codes. The number of drugs dispensed are shown of drugs that are contraindi-
cated for age
c Cholecalciferol and the combination with calcium carbonate have been compiled on one line. Temazepam and Zoplicon have been compiled on 
one line
ATC anatomical therapeutic chemical, SD standard deviation
Name of drug (ATC code) Childrena Dispensingsb Mean age (SD) Potential risk, reason for contraindication
Cholecalciferol (A11CC05)c 30,301 60,034 13.3 (4.0) The oral suspension of cholecalciferol and 
the combination with calcium carbonate is 
contraindicated in children aged 17 years 
and below because it contains a high dose of 
Vitamin D
Calcium carbonate/cholecalciferol (A12AX) 2518 6434 12.7 (3.9)
Metoclopramide (A03FA01) 6253 7056 12.0 (4.8) Contraindicated in children below the age of 1. 
Metoclopramide suppositories are contraindi-
cated in children aged 17 and below because of 
the high risk of extrapyramidal disorders
Doxycycline (systemic) (J01AA02) 2670 2904 10.4 (1.8) Contraindicated in children below the age of 
8 (infections) and 12 years (facial rosacea), 
because of the risk of tooth staining
Dimetindene (R06AB03) 1560 2106 0.8 (0.4) Contraindicated in children below the age of 1, 
because the sedative effect can be associated 
with episodes of sleep apnoea
Levomenthol (R05X) 904 936 0.9 (0.7) Contraindicated in children below the age of 2, 
because substances containing menthol have 
been reported to cause instant collapse or laryn-
gospasm
Fludrocortisone/neomycin/polymyxine B/lido-
caine combination (S02CA07)
800 891 1.4 (0.6) Contraindicated in children below the age of 2 
because of the possibility of increased absorp-
tion of neomycine and the kidney function may 
not be fully developed. There is also a potential 
risk of nephrotoxicity and ototoxicity due to 
neomycin
Promethazine (R06AD02) 643 696 1.9 (0.4) Contraindicated in children below the age of 
2, because promethazine may lead to severe 
respiratory depression and apnea. A poten-
tial association of promethazine use with the 
sudden infant death syndrome has also been 
reported
Levodopa/Benserazide combination (N04BA02) 268 496 11.4 (4.8) Contraindicated in children and adolescents 
aged 24 years and below. Animal studies have 
suggested that benserazide may cause skeletal 
abnormalities if administered before skeletal 
development is complete
Temazepam (N05CD07)c 226 352 7.0 (3.4) Contraindicated in children aged 11 years and 
below because the safety and effectiveness in 
children have not been established
Zoplicon (N05CF01) 171 283 14.4 (3.9)
Loperamide (A07DA03) 112 129 1.3 (0.8) Contraindicated in children below the age of 2 
because use of loperamide has been associated 
with fatal episodes of paralytic ileus
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drugs that were dispensed since birth to determine the 1-year 
cumulative incidence and prevalence.
Our study also has several limitations. Our data do not 
include the drugs that were dispensed by hospital pharma-
cies where the numbers of contraindicated drugs that were 
dispensed may be higher. No information about the month 
of birth was available. Therefore, we only included drugs in 
our analysis where the contraindication for age was based 
on the number of years and not months. Also, no informa-
tion was available with regard to the indication of the drugs 
prescribed.
Conclusion
The results of this study showed that a substantial percentage 
of children received a dispensed drug which is contraindi-
cated for that age. This is more common in females than in 
males. Gender differences in disease prevalence or health-
care may explain this observation. We also observed that 
the information about the contraindication (contraindica-
tion or warning and the reason) is limited and not consistent 
between the different information sources. Since prescribing 
an on-label drug can be inaccurate, as much as prescribing 
an contraindication drug can be good practice, it is important 
that all prescribers and healthcare professionals are informed 
sufficiently about the contraindications. Further research is 
needed to investigate the reasons for prescribing particular 
drugs despite their contraindication for age, and the gender 
differences that were found in this study.
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